FindTrial
Sign In

Mechanisms and efficacy of artemether in the treatment of rosacea

Mechanisms and efficacy of artemether in the treatment of rosacea

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019906
Enrollment
Unknown
Registered
2018-12-08
Start date
2016-10-01
Completion date
Unknown
Last updated
2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne rosacea

Interventions

Group 1:Artemether
Group 2:Metronidazole

Sponsors

Shanghai Pudong New Area Zhoupu Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: According to the criteria of the National Academy of Rosacea, 120 patients with mild to moderate rosacea and 120 patients with follicular Demodex were randomly divided into two groups, 60 cases in each group; Sign informed consent to the patient; Aged 18 to 70 years male and female.

Exclusion criteria

Exclusion criteria: Acne, seborrheic dermatitis, steroid dermatitis and lupus erythematosus were excluded. At present, glucocorticoids, or tetracyclines (tetracycline, doxycycline, memantine, etc.) are currently in use and cannot be followed up.

Design outcomes

Primary

MeasureTime frame
Impetigo;erythema;Blood capillary;—

Countries

China

Contacts

Public ContactGuojiang Wang

Department of Dermatology, Zhouyuan Hospital

zpyywang@163.com+86 13671675186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026